Literature DB >> 25867718

Sequential or concomitant therapy for eradication of Helicobacter pylori infection: A systematic review and meta-analysis.

Joon Sung Kim1, Sung Min Park1, Byung-Wook Kim1.   

Abstract

BACKGROUND AND AIM: Eradication of Helicobacter pylori (H. pylori) infection with triple therapy (TT) has declined in many countries prompting the search for alternative regimens. Sequential therapy (ST) and concomitant therapy (CT) have been suggested as first-line regimens in areas of high clarithromycin resistance. We performed a meta-analysis to compare the eradication rates of CT with ST for H. pylori.
METHODS: A comprehensive literature search for studies comparing the efficacy of CT with ST was performed. Dichotomous data were pooled to obtain the odds ratio (OR) of the eradication rate with 95% confidence intervals (CIs). The eradication rates were considered both on an intention-to-treat (ITT) and on a per-protocol (PP) bases.
RESULTS: A total of 7 studies provided data on 2412 adult patients. Pooled estimates of the studies revealed no significant differences between CT and ST. The pooled OR was 1.116 (95% CI: 0.795-1.567, P = 0.526) for ITT analysis and 1.153 (95% CI: 0.793-1.677, P = 0.455) for PP analysis. There was no difference in the rate of adverse events (OR: 1.229, 95% CI: 0.971-1.556, P = 0.086) and compliance (OR: 0.945, 95% CI: 0.722-1.237, P = 0.681) between the two regimens. Subgroup analysis was performed to compare CT of 10 days and 5 days with ST of 10 days. The pooled OR was 1.518 for CT of 10 days and 0.636 for CT of 5 days.
CONCLUSIONS: CT regimens did not achieve higher eradication rates compared with the ST regimen. The adverse events and adherence to medications were not different between the two regimens.
© 2015 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  Helicobacter pylori; concomitant therapy; meta-analysis; sequential therapy

Mesh:

Substances:

Year:  2015        PMID: 25867718     DOI: 10.1111/jgh.12984

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  13 in total

Review 1.  Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis.

Authors:  Alicia C Marin; Olga P Nyssen; Adrian G McNicholl; Javier P Gisbert
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

2.  Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial.

Authors:  Hassan Seddik; Hanae Boutallaka; Ilham Elkoti; Fouad Nejjari; Reda Berraida; Sanaa Berrag; Khaoula Loubaris; Sara Sentissi; Ahmed Benkirane
Journal:  Eur J Clin Pharmacol       Date:  2019-01-29       Impact factor: 2.953

3.  The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.

Authors:  Sho Suzuki; Takuji Gotoda; Chika Kusano; Kunio Iwatsuka; Mitsuhiko Moriyama
Journal:  Am J Gastroenterol       Date:  2016-05-17       Impact factor: 10.864

Review 4.  Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis.

Authors:  Youhua Wang; Rulin Zhao; Ben Wang; Qiaoyun Zhao; Zhen Li; Liya Zhu-Ge; Wenzhu Yin; Yong Xie
Journal:  Eur J Clin Pharmacol       Date:  2017-10-08       Impact factor: 2.953

Review 5.  Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions.

Authors:  Aleksandra Sokic-Milutinovic; Tamara Alempijevic; Tomica Milosavljevic
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

Review 6.  Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: A systematic review and meta-analysis.

Authors:  Zhi-Qiang Song; Li-Ya Zhou
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

7.  The clearance effect of bovine anti-Helicobacter pylori antibody-containing milk in O blood group Helicobacter pylori-infected patients: a randomized double-blind clinical trial.

Authors:  Dailun Hu; Feng Zhang; Jikun Zhou; Baohong Xu; Hongying Zhang; Huiqin Qiang; Shuguang Ren; Baoen Shan; Changfu Yin; Zhitao Zhang; Xian Wang; Chuan Zhao; Zhongli Shi
Journal:  J Transl Med       Date:  2015-06-30       Impact factor: 5.531

8.  Role of concomitant therapy for Helicobacter pylori eradication: A technical note.

Authors:  Giuseppe Losurdo; Floriana Giorgio; Andrea Iannone; Mariabeatrice Principi; Michele Barone; Alfredo Di Leo; Enzo Ierardi
Journal:  World J Gastroenterol       Date:  2016-10-14       Impact factor: 5.742

Review 9.  First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines.

Authors:  Vincenzo De Francesco; Annamaria Bellesia; Lorenzo Ridola; Raffaele Manta; Angelo Zullo
Journal:  Ann Gastroenterol       Date:  2017-06-01

10.  Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology.

Authors:  Shivaram Prasad Singh; Vineet Ahuja; Uday C Ghoshal; Govind Makharia; Usha Dutta; Showkat Ali Zargar; Jayanthi Venkataraman; Amit Kumar Dutta; Asish K Mukhopadhyay; Ayaskanta Singh; Babu Ram Thapa; Kim Vaiphei; Malathi Sathiyasekaran; Manoj K Sahu; Niranjan Rout; Philip Abraham; Prakash Chandra Dalai; Pravin Rathi; Saroj K Sinha; Shobna Bhatia; Susama Patra; Ujjala Ghoshal; Ujjal Poddar; Venigalla Pratap Mouli; Vikram Kate
Journal:  Indian J Gastroenterol       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.